Cargando…
Prospective pharmacological methodology for establishing and evaluating anti-cancer drug resistant cell lines
BACKGROUND: Cell lines are often used to assess the resistance of anticancer drugs when in vivo analysis is not possible. However, the process for establishing anti-cancer drug resistance in cell cultures in vitro and the subsequent method of then evaluating resistance are not clearly established. T...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8464141/ https://www.ncbi.nlm.nih.gov/pubmed/34560848 http://dx.doi.org/10.1186/s12885-021-08784-7 |
_version_ | 1784572559837102080 |
---|---|
author | Yu, Hoon Kim, Dong-Jin Choi, Hye-Young Kim, So Myoung Rahaman, Md. Intazur Kim, Young-Hoon Kim, So Won |
author_facet | Yu, Hoon Kim, Dong-Jin Choi, Hye-Young Kim, So Myoung Rahaman, Md. Intazur Kim, Young-Hoon Kim, So Won |
author_sort | Yu, Hoon |
collection | PubMed |
description | BACKGROUND: Cell lines are often used to assess the resistance of anticancer drugs when in vivo analysis is not possible. However, the process for establishing anti-cancer drug resistance in cell cultures in vitro and the subsequent method of then evaluating resistance are not clearly established. Traditionally, the IC(50) is the most commonly used indicator of resistance evaluation but it cannot represent the effectiveness of anti-cancer drugs in a clinical setting and lacks reliability because it is heavily affected by the cell doubling time. Hence, new indicators that can evaluate anti-cancer drug resistance are needed. METHODS: A novel resistance evaluation methodology was validated in this present study by establishing sunitinib resistance in renal cell carcinoma cells and assessing the cross-resistance of five different anti-cancer drugs. RESULTS: It was confirmed in this present study that the IC(50) does not reflect the cell proliferation rates in a way that represents anti-cancer drug resistance. An alternative indicator that can also be clinically meaningful when using in vitro cell line systems is GI(100). Additionally, the GR(100) allows different cell populations to be calibrated on the same basis when multiple experimental results are compared. CONCLUSION: Since the GR(100) has properties that indicate the efficiency of anti-cancer drugs, both the efficacy and GR(100) of a particular anti-cancer drug can be used to effectively assess the resistance. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-08784-7. |
format | Online Article Text |
id | pubmed-8464141 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-84641412021-09-27 Prospective pharmacological methodology for establishing and evaluating anti-cancer drug resistant cell lines Yu, Hoon Kim, Dong-Jin Choi, Hye-Young Kim, So Myoung Rahaman, Md. Intazur Kim, Young-Hoon Kim, So Won BMC Cancer Research BACKGROUND: Cell lines are often used to assess the resistance of anticancer drugs when in vivo analysis is not possible. However, the process for establishing anti-cancer drug resistance in cell cultures in vitro and the subsequent method of then evaluating resistance are not clearly established. Traditionally, the IC(50) is the most commonly used indicator of resistance evaluation but it cannot represent the effectiveness of anti-cancer drugs in a clinical setting and lacks reliability because it is heavily affected by the cell doubling time. Hence, new indicators that can evaluate anti-cancer drug resistance are needed. METHODS: A novel resistance evaluation methodology was validated in this present study by establishing sunitinib resistance in renal cell carcinoma cells and assessing the cross-resistance of five different anti-cancer drugs. RESULTS: It was confirmed in this present study that the IC(50) does not reflect the cell proliferation rates in a way that represents anti-cancer drug resistance. An alternative indicator that can also be clinically meaningful when using in vitro cell line systems is GI(100). Additionally, the GR(100) allows different cell populations to be calibrated on the same basis when multiple experimental results are compared. CONCLUSION: Since the GR(100) has properties that indicate the efficiency of anti-cancer drugs, both the efficacy and GR(100) of a particular anti-cancer drug can be used to effectively assess the resistance. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-08784-7. BioMed Central 2021-09-25 /pmc/articles/PMC8464141/ /pubmed/34560848 http://dx.doi.org/10.1186/s12885-021-08784-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Yu, Hoon Kim, Dong-Jin Choi, Hye-Young Kim, So Myoung Rahaman, Md. Intazur Kim, Young-Hoon Kim, So Won Prospective pharmacological methodology for establishing and evaluating anti-cancer drug resistant cell lines |
title | Prospective pharmacological methodology for establishing and evaluating anti-cancer drug resistant cell lines |
title_full | Prospective pharmacological methodology for establishing and evaluating anti-cancer drug resistant cell lines |
title_fullStr | Prospective pharmacological methodology for establishing and evaluating anti-cancer drug resistant cell lines |
title_full_unstemmed | Prospective pharmacological methodology for establishing and evaluating anti-cancer drug resistant cell lines |
title_short | Prospective pharmacological methodology for establishing and evaluating anti-cancer drug resistant cell lines |
title_sort | prospective pharmacological methodology for establishing and evaluating anti-cancer drug resistant cell lines |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8464141/ https://www.ncbi.nlm.nih.gov/pubmed/34560848 http://dx.doi.org/10.1186/s12885-021-08784-7 |
work_keys_str_mv | AT yuhoon prospectivepharmacologicalmethodologyforestablishingandevaluatinganticancerdrugresistantcelllines AT kimdongjin prospectivepharmacologicalmethodologyforestablishingandevaluatinganticancerdrugresistantcelllines AT choihyeyoung prospectivepharmacologicalmethodologyforestablishingandevaluatinganticancerdrugresistantcelllines AT kimsomyoung prospectivepharmacologicalmethodologyforestablishingandevaluatinganticancerdrugresistantcelllines AT rahamanmdintazur prospectivepharmacologicalmethodologyforestablishingandevaluatinganticancerdrugresistantcelllines AT kimyounghoon prospectivepharmacologicalmethodologyforestablishingandevaluatinganticancerdrugresistantcelllines AT kimsowon prospectivepharmacologicalmethodologyforestablishingandevaluatinganticancerdrugresistantcelllines |